Table 1.

Baseline characteristics of the study population

	Liraglutide n  = 33	Glimepiride n  =  29	p value
Age, years	60.8 (7.6)	63.0 (6.8)	0.240a
Male sex	24 (72.7)	21 (72.4)	1.000b
Diabetes duration, years	5 (1, 10)	1 (3, 7)	0.368c
Smoking	3 (9.1)	4 (13.8)	0.852b
BMI, kg/m2	30.5 (4.4)	29.0 (3.2)	0.152a
Body weight, kg	91.8 (15.9)	89.0 (9.9)	0.411a
Waist circumference, cm	109.0 (13.0)	106.3 (9.7)	0.366a
Mean systolic BP, mmHg	131.9 (14.0)	129.3 (10.9)	0.414a
Mean diastolic BP, mmHg	76.7 (7.9)	77.2 (7.9)	0.838a
eGFR, mL/min/1.72 m2	88.3 (15.0)	87.4 (13.1)	0.799a
Complications
Hypertension	29 (87.9)	21 (72.4)	0.224b
Hyperlipidemia	25 (75.8)	23 (79.3)	0.980b
Myocardial infarction	10 (30.3)	11 (37.9)	0.714b
Stroke	1 (3)	2 (6.9)	0.902b
Proliferative retinopathy	1 (3)	1 (3.4)	1.000b
Treatment
Antiplatelet therapy	11 (33.3)	12 (41.4)	0.696b
Anticoagulant treatment	3 (9.1)	1 (3.4)	0.714b
ACE inhibitors/ARB blockers	25 (75.8)	20 (69)	0.754b
Beta-blockers	14 (42.4)	13 (44.8)	1.000b
Calcium inhibitors	13 (39.4)	10 (34.5)	0.894b
Diuretics	11 (33.3)	6 (20.7)	0.408b
Statins	22 (66.7)	24 (82.8)	0.248b
Biochemical parameters
HbA1c, mmol/mol	54 (50, 60)	50 (49, 54)	0.036c
Triglycerides, mmol/L	2.0 (1.4, 2.6)	1.5 (1.0, 2.2)	0.029c
Total cholesterol, mmol/L	4.4 (4.0, 6.0)	4.5 (3.7, 4.8)	0.370c
LDL-cholesterol, mmol/L	2.8 (1.2)	2.5 (1.0)	0.440a
HDL-cholesterol, mmol/L	1.1 (0.3)	1.2 (0.3)	0.417a

Quantitative data are mean (SD) or median (1st quartile, 3rd quartile), and categorical data are n (%)

ARB angiotensin receptor blockers; BP blood pressure; eGFR estimated glomerular filtration rate; HbA1c glycated hemoglobin A1c

^aStudent’s t test was used

^bDoubled one-sided p value from Fisher’s exact test

^cMann–Whitney U test was used